Clinical Studies - Genacol South Africa

Science Behind Genacol

At Genacol, we care about our customers’ joint health and well-being. This is why we have been committed for more than 20 years to a quest for excellence driven by a strong desire for technical and scientific innovation.

A Unique Patented Technology

Thanks to Genacol’s patented enzymatic hydrolysis technology, the AminoLock® Sequence Technology, we obtain ultra-hydrolyzed collagen from a bovine source: AminoLock® Collagen. This unique collagen peptide has the lowest molecular weight in the world at less than 1 kilodalton (kDa) and is specifically designed to reduce joint pain associated with osteoarthritis. CA Patent Number 2950096 | US Patent Number 11.040.081

McGill Research: AminoLock® Collagen Bioavailability

Collaborative Research results

This collaborative research project with McGill University has demonstrated better bioavailability of AminoLock® Collagen. In addition, it showed that several peptides important for joint health are better absorbed and metabolized than generic collagen. These essential peptides provided by our proprietary ingredient have been measured, along with their known joint health benefits, confirming that Genacol® AminoLock® Collagen is indeed different and unique. 1. Larder, C.E.; Iskandar, M.M.; Sabally, K.; Kubow, S. Complementary and efficient methods for di- and tri-peptide analysis and amino acid quantification from simulated gastrointestinal digestion of collagen hydrolysate. LWT 2022, 155, 112880, doi:https://doi.org/10.1016/j.lwt.2021.112880. 2.Larder, C.E.; Iskandar, M.M.; Kubow, S. Assessment of Bioavailability after In Vitro Digestion and First Pass Metabolism of Bioactive Peptides from Collagen Hydrolysates. Current Issues in Molecular Biology 2021, 43, 1592-1605, doi:10.3390/cimb43030113.

Bruyère Clinical Study: Effectiveness on Joint Pain

Clinical Study Result

After six months of treatment, the results showed a significant increase in the proportion of patients reporting a notable reduction in joint pain when they consumed Genacol AminoLock® Collagen compared to patients on placebo. Bruyère O, et al. Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo-controlled study. Complement Ther Med (2012).

The first study was a multicenter randomized placebo-controlled trial carried out in Belgium by world-renowned researchers in the field of osteoarthritis (10).

Patients suffered from joint pain in various areas: upper body (shoulder, elbow, wrist), lower back or lower body (hip, knee). Over 140 patients were randomly assigned to receive either 1200 mg of Genacol® AminoLock® Collagen or a placebo. The study was well balanced (baseline patient characteristics) and of excellent quality. The authors used a visual analog scale (VAS), the Gold Standard reference test, for the subjective assessment of pain. The VAS scale is notably used to demonstrate the clinical efficacy of analgesic drugs. It is recognized by regulatory agencies such as the US Federal Drug Agency (FDA) and the Canadian Therapeutic Products Directorate (TPD).

Parm Clinical Study: Improving Joint Space

Clinical Study Result

After six months of treatment, the results of this clinical study indicate that Genacol® AminoLock Collagen may not only reduce pain and improve knee function in patients with osteoarthritis but also prevent joint space degradation. Maria Lourdes R. Bernardo and Alfredo C. Azarcon, Jr. Effects of Oral Collagen Treatment on the Media Knee Joint Space and Functional Outcome among Veterans Memorial Medical Center Patients Diagnosed with Osteoarthritis of the Knee (2012).

A second clinical study was carried out in a Veterans Hospital Center in the Philippines; this time, the study focused on patients suffering from knee osteoarthritis (12). A total of 113 patients were randomly assigned to receive either a daily dose of 1200 mg of Genacol® AminoLock® Collagen or a daily dose of 200 mg of aceclofenac, a standard non-steroidal anti-inflammatory drug (NSAID). The authors used the Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC). The latter is often considered the reference test for knee osteoarthritis since it assesses pain and joint function in several daily situations of rest and activity (13).

Clinical Study Result

After 6 months of treatment, this clinical study showed that taking AminoLock Collagen combined with an exercise program reduced pain, improved general functional status and caused changes to intra-articular and periarticular structures compared to patients on placebo. Chan, R., & De Los Reyes, M. F. Effect of Collagen Hydrolysate as an adjuvant treatment to Exercise for Knee Osteoarthritis (2016).

A third clinical study was developed at the University of Santo Tomas Hospital in the Philippines. The objective was to determine whether taking Genacol® AminoLock® Collagen, combined with a physical exercise program, shows a significant reduction of cartilage wear and tear. In the study, participants were randomly selected. A treatment group took three 400 mg capsules of Genacol® Aminolock® Collagen daily for six months, and a control group (n=53) took a placebo. The two groups were subjected to a standard program. Evaluations were carried out at the start and end of the six months. These evaluations included reviewing participants’ medical records, a physical exam, WOMAC evaluations and ultrasonography of both knees. Calculation of means and standard deviations were carried out for demographic information, visual analogue scale (VAS) pain evaluations, WOMAC evaluations and ultrasound measurements.

Results: in general, WOMAC and VAS evaluations decreased compared to the initial evaluations of both treatment groups. There was a significant increase of 62.5 % in the execution of the exercise program by the treatment group who took Genacol® Aminolock® Collagen. The Genacol® AminoLock® Collagen group demonstrated a fairly significant change in the average level of cartilage wear compared to the placebo group. The result of central cartilage compared to the placebo group. Conclusions: Our clinical team demonstrated that Genacol® Aminolock® Collagen, combined with an exercise program, reduced pain, improved general functional status and produced changes in the intra-articular and peri-articular structures (that is, an improvement in the level of wear of the cartilage and a decrease in the movement of the lateral meniscus of patients with osteoarthritis of the knee.

Type to search